Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.3950
+0.0050 (1.28%)
At close: Apr 17, 2026, 4:00 PM EDT
0.3900
-0.0050 (-1.27%)
After-hours: Apr 17, 2026, 7:35 PM EDT
Scienture Holdings Employees
As of December 31, 2025, Scienture Holdings had 9 total employees, including 4 full-time and 5 part-time employees. The number of employees decreased by 10 or -52.63% compared to the previous year.
Employees
9
Change (1Y)
-10
Growth (1Y)
-52.63%
Revenue / Employee
$47,957
Profits / Employee
-$4,612,474
Market Cap
16.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 9 | -10 | -52.63% | 4 | 5 |
| Dec 31, 2024 | 19 | 0 | - | 14 | 5 |
| Jun 30, 2024 | 19 | - | - | 14 | 5 |
| Dec 31, 2023 | 19 | - | - | 14 | 5 |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
| Jin Medical International | 273 |
| SeaStar Medical Holding | 17 |
| Genenta Science | 9 |
| Traws Pharma | 7 |
SCNX News
- 19 days ago - SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - GlobeNewsWire
- 2 months ago - SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 3 months ago - SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment - GlobeNewsWire
- 4 months ago - SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - GlobeNewsWire
- 4 months ago - SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 4 months ago - SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - GlobeNewsWire
- 5 months ago - SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - GlobeNewsWire